Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASTRO 2022 | Phase II study of response-adapted ultra-low dose radiotherapy for B-cell lymphoma

Chelsea Pinnix, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the study design, rationale, and key results of a study of response-adapted ultra-low dose radiotherapy for B-cell lymphoma. Patients are typically treated with higher doses of radiotherapy, which can result in acute side effects to the orbital region. The Phase II prospective trial aimed to achieve the same disease outcomes with ultra-low doses of response-adapted radiotherapy compared to the standard of care upfront higher dose, to avoid toxicity effects. It was found that patients receiving response-adapted ultra-low dose radiotherapy had an overall survival (OS) rate of 98%, a two-year local control rate of 91% and limited, mild side effects. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.